Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Medicinal Chemistry

Background:

• Src homology containing protein tyrosine phosphatase 2 (SHP2) is a key oncogenic phosphatase implicated in various cancers.
• Traditional SHP2 inhibitors targeting catalytic sites exhibit poor cell permeability and bioavailability, limiting clinical efficacy.
• Emerging allosteric inhibitors demonstrate potent SHP2 inhibition and promising clinical progress in solid tumors.

Purpose of the Study:

• To review the development of small-molecule SHP2 inhibitors for cancer treatment.
• To analyze structure-activity relationships (SAR) of identified SHP2 inhibitors.
• To guide future development of SHP2 inhibitors with enhanced selectivity, oral bioavailability, and physicochemical properties.

Main Methods:

• Literature review of published studies on SHP2 inhibitors.
• Analysis of structure-activity relationship data for small-molecule SHP2 inhibitors.
• Evaluation of clinical trial progress for SHP2 allosteric inhibitors in solid tumors.

Main Results:

• Numerous potent SHP2 allosteric inhibitors have been identified.
• Clinical trials using SHP2 allosteric inhibitors have shown significant progress in treating solid tumors.
• SAR studies provide insights into optimizing inhibitor properties.

Conclusions:

• SHP2 allosteric inhibitors represent a promising therapeutic strategy for cancer.
• Further optimization of selectivity, bioavailability, and physicochemical properties is crucial for clinical success.
• This review provides a foundation for designing next-generation SHP2 inhibitors.